Glaxo Decides Not To Pursue U.K. Flu Awareness Campaign For Relenza
Executive Summary
The potential negative impact on the U.K.' s National Health Service drug budget may be one factor behind Glaxo Wellcome's decision not to launch a flu awareness campaign for its neuraminidase inhibitor Relenza (zanamivir) in the U.K.